CIBC Private Wealth Group
AIMT

CIBC Private Wealth Group’s Aimmune Therapeutics AIMT Stock Holding History

CIBC Private Wealth Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,251
Closed -$376K – 972
2019
Q4 		$376K Buy
+11,251
New +$315K ﹤0.01% 756
2018
Q3 		– Sell
-950
Closed -$26K – 1883
2018
Q2 		$26K Buy
950
+694
+271% +$21.2K ﹤0.01% 1341
2018
Q1 		$8K Buy
+256
New +$9.01K ﹤0.01% 1583

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CIBC Private Wealth Group's AIMT Position: Q1 2020 in Review

CIBC Private Wealth Group sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 11,251 shares — an estimated $376K sold.

CIBC Private Wealth Group first reported a position in AIMT in Q1 2018 and held it in 3 quarters. The position peaked at $376K in Q4 2019. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

  • CIBC Private Wealth Group reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
  • CIBC Private Wealth Group sold 11,251 Aimmune Therapeutics shares in Q1 2020, an estimated $376K.
  • CIBC Private Wealth Group first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 3 quarters.
  • CIBC Private Wealth Group's Aimmune Therapeutics position peaked at $376K in Q4 2019.
  • 161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on CIBC Private Wealth Group's 13F filing for Q1 2020, filed 15 May 2020.